Genzyme's Revenue Set to Climb

Genzyme (GENZ Quote) reported a 22% increase in fourth-quarter revenue, but the biotech company's top line didn't quite reach Wall Street's expectations.

The Cambridge, Mass., company reported $722 million in revenue in the fourth quarter, up from $591 million a year earlier. Analysts surveyed by Thomson First Call were expecting revenue of $729.9 million.

Sales of one of its top drugs, Cerezyme, climbed 6% to $232 million. Cerezyme is a treatment for Gaucher disease, an inherited condition that causes the buildup of fatty deposits in some organs and bones. Fewer than 10,000 people in the world have the disease, which can lead to spleen and liver enlargement, anemia and other problems. ...